Cingulate Inc.
CINGWNasdaq
$0.02
↑ +8.5%Jul 16 close · end-of-day
Price
1Y↓ -48.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$213,155.73
Enterprise Value
-$25.7M
P/E
—
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$27.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-147.9%
ROIC
—
Debt / Equity
—
Net Cash
$25.9M
Return 1Y
-53.5%
Company profile
Cingulate Inc. focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
- CEO
- Shane J. Schaffer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Kansas
- Website
- cingulate.com
Management & directors
- Brams MatthewEVP and Chief Medical Officer
- Callahan Jennifer L.EVP and CFO
- Patel Nilay DahyabhaiEVP, CLO and CCO
- Schaffer Shane J.Chief Executive Officer
- Silva Raul R.EVP and CSO
Roles derived from SEC Form 4 filings.
Earnings
CINGW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.95↓ -10.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.1M | -$20.7M | -$17.5M | -$22.8M | -$15.6M | -$19.9M |
| Net income | -$7.2M | -$20.7M | -$17.7M | -$23.5M | -$16.6M | -$22.4M |
| Diluted EPS | — | — | -$29.35 | -$311.99 | -$10.86 | -$4.44 |
| Operating cash flow | -$6.8M | -$10.4M | -$15.9M | -$15.0M | -$18.5M | -$17.2M |
| Free cash flow | -$7.2M | -$11.2M | -$16.0M | -$15.3M | -$18.7M | -$17.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.2M | -$3.3M | -$6.2M | -$3.7M | -$4.6M | -$6.0M | -$5.6M | -$7.9M |
| Net income | -$3.2M | -$4.1M | -$6.2M | -$3.9M | -$5.0M | -$7.3M | -$6.3M | -$9.3M |
| Diluted EPS | -$5.47 | -$2.34 | $4.16 | -$1.06 | -$1.09 | -$1.35 | -$0.94 | -$0.95 |
| Operating cash flow | -$1.7M | -$3.9M | -$4.1M | -$4.6M | -$4.8M | -$4.2M | -$3.6M | -$6.9M |
| Free cash flow | -$1.8M | -$4.0M | -$4.3M | — | — | -$4.2M | — | -$7.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 4, 2026
Jun 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-09 | Silva Raul R.· EVP and CSO | Award | 4,526 | $0.00 | $0.00 | filing |
| 2026-03-09 | Silva Raul R.· EVP and CSO | Tax withholding | 1,828 | $0.00 | $0.00 | filing |
| 2026-03-09 | Schaffer Shane J.· Chief Executive Officer | Award | 6,862 | $0.00 | $0.00 | filing |
| 2026-03-09 | Schaffer Shane J.· Chief Executive Officer | Tax withholding | 2,959 | $0.00 | $0.00 | filing |
| 2026-03-09 | Callahan Jennifer L.· EVP and CFO | Award | 15,329 | $0.00 | $0.00 | filing |
| 2026-03-09 | Callahan Jennifer L.· EVP and CFO | Tax withholding | 6,427 | $0.00 | $0.00 | filing |
| 2026-03-09 | Patel Nilay Dahyabhai· EVP, CLO and CCO | Award | 5,475 | $0.00 | $0.00 | filing |
| 2026-03-09 | Patel Nilay Dahyabhai· EVP, CLO and CCO | Tax withholding | 2,086 | $0.00 | $0.00 | filing |
| 2026-03-09 | Brams Matthew· EVP and Chief Medical Officer | Award | 4,526 | $0.00 | $0.00 | filing |
| 2026-03-09 | Brams Matthew· EVP and Chief Medical Officer | Tax withholding | 1,025 | $0.00 | $0.00 | filing |
| 2026-02-13 | Hargroves Thomas Jeffrey | Buy | 97,276 | $5.04 | $490,271.04 | filing |
| 2026-02-06 | Werth Peter J. | Buy | 19,455 | $5.04 | $98,053.20 | filing |
| 2026-02-06 | Schaffer Shane J.· Chief Executive Officer | Buy | 6,809 | $5.04 | $34,317.36 | filing |
| 2026-02-06 | Callahan Jennifer L.· SVP and CFO | Buy | 4,864 | $5.04 | $24,514.56 | filing |
| 2026-02-06 | Brams Matthew· EVP and Chief Medical Officer | Buy | 1,946 | $5.04 | $9,807.84 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.